- Home
- TANH vs ZVSA Comparison
TANH vs ZVSA Comparison
Compare TANH & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TANH
- ZVSA
- Stock Information
- Founded
- TANH 2001
- ZVSA 2014
- Country
- TANH China
- ZVSA United States
- Employees
- TANH N/A
- ZVSA N/A
- Industry
- TANH
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- TANH
- ZVSA Health Care
- Exchange
- TANH Nasdaq
- ZVSA Nasdaq
- Market Cap
- TANH 3.5M
- ZVSA 3.0M
- IPO Year
- TANH 2015
- ZVSA N/A
- Fundamental
- Price
- TANH $2.00
- ZVSA $0.69
- Analyst Decision
- TANH
- ZVSA
- Analyst Count
- TANH 0
- ZVSA 0
- Target Price
- TANH N/A
- ZVSA N/A
- AVG Volume (30 Days)
- TANH 33.3K
- ZVSA 1.5M
- Earning Date
- TANH 07-07-2025
- ZVSA 08-08-2025
- Dividend Yield
- TANH N/A
- ZVSA N/A
- EPS Growth
- TANH N/A
- ZVSA N/A
- EPS
- TANH N/A
- ZVSA N/A
- Revenue
- TANH $42,940,136.00
- ZVSA N/A
- Revenue This Year
- TANH N/A
- ZVSA N/A
- Revenue Next Year
- TANH N/A
- ZVSA N/A
- P/E Ratio
- TANH N/A
- ZVSA N/A
- Revenue Growth
- TANH N/A
- ZVSA N/A
- 52 Week Low
- TANH $1.45
- ZVSA $0.47
- 52 Week High
- TANH $38.40
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- TANH 45.28
- ZVSA 53.43
- Support Level
- TANH $1.95
- ZVSA $0.61
- Resistance Level
- TANH $2.14
- ZVSA $0.73
- Average True Range (ATR)
- TANH 0.14
- ZVSA 0.07
- MACD
- TANH -0.01
- ZVSA 0.00
- Stochastic Oscillator
- TANH 21.21
- ZVSA 36.53
About TANH Tantech Holdings Ltd.
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company through its subsidiaries is engaged in the production and distribution of household products along with a trading business which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments; the Consumer Product segment, and the Electric Vehicle (EV) segment.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.